Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Gilabert M, Bertucci F, Esterni B, et al. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors. Anticancer Res. 2011 Mar;31(3):1079–1086.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012 Oct 4;490(7418):61–70.
   PubMed Web of Science ®Google Scholar
• Di Leva G, Cheung DG, Croce CM. miRNA clusters as therapeutic targets for hormone-resistant breast cancer. Expert Rev Endocrinol Metab. 2015;10(6):607–617.
   PubMed Web of Science ®Google Scholar
• Yu Z, Pestell RG. Small non-coding RNAs govern mammary gland tumorigenesis. J Mammary Gland Biol Neoplasia. 2012 Mar;17(1):59–64.
   PubMed Web of Science ®Google Scholar
• Wang G, Gormley M, Qiao J, et al. Cyclin D1-mediated microRNA expression signature predicts breast cancer outcome. Theranostics. 2018;8(8):2251–2263.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu B, Zhang XP. Effects of miRNAs on functions of breast cancer stem cells and treatment of breast cancer. Onco Targets Ther. 2018;11:4263–4270.
   PubMed Web of Science ®Google Scholar
• Xu H, Yu S, Liu Q, et al. Recent advances of highly selective CDK4/6 inhibitors in breast cancer. J Hematol Oncol. 2017 Apr 24;10(1):97.
   PubMedGoogle Scholar
• Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000 Aug 17;406(6797):747–752.
   PubMed Web of Science ®Google Scholar
• Shimelis H, LaDuca H, Hu C, et al. Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing. J Natl Cancer Inst. 2018 Aug;110(8):855-862-.
   PubMedGoogle Scholar
• Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014 Apr;2(4):361–370.
   PubMed Web of Science ®Google Scholar
• Velasco-Velazquez M, Jiao X, De La Fuente M, et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 2012 Aug 1;72(15):3839–3850.
   PubMed Web of Science ®Google Scholar
• Jiao X, Velasco-Velazquez MA, Wang M, et al. CCR5 governs DNA damage repair and breast cancer stem cell expansion. Cancer Res. 2018 Apr 1;78(7):1657–1671.
   PubMed Web of Science ®Google Scholar
• Casimiro MC, Crosariol M, Loro E, et al. ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice. J Clin Invest. 2012 Mar;122(3):833–843.
   PubMed Web of Science ®Google Scholar
• Asghar U, Witkiewicz AK, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015 Feb;14(2):130–146.
   PubMed Web of Science ®Google Scholar
• Shah AN, Cristofanilli M. The growing role of CDK4/6 inhibitors in treating hormone receptor-positive advanced breast cancer. Curr Treat Options Oncol. 2017 Jan;18(1):6.
   PubMed Web of Science ®Google Scholar
• Sablin MP, Ricci F, Loirat D, et al. [Cell cycle inhibitors in endocrine receptor positive breast cancer]. Bull Cancer. 2017 Feb;104(2):114–122.
   PubMed Web of Science ®Google Scholar
• Di Sante G, Casimiro MC, Li Z, et al. D-type cyclins and gene transcription. In: Hinds PW, Brown NE, editors. D-Type Cyclins Cancer. Cham (Switzerland): Springer International Publishing; 2018. p. 61–90.
   Google Scholar
• Swaffer MP, Jones AW, Flynn HR, et al. Quantitative phosphoproteomics reveals the signaling dynamics of cell-cycle kinases in the fission yeast schizosaccharomyces pombe. Cell Rep. 2018 Jul 10;24(2):503–514.
   PubMed Web of Science ®Google Scholar
• Swaffer MP, Jones AW, Flynn HR, et al. CDK substrate phosphorylation and ordering the cell cycle. Cell. 2016 Dec 15;167(7):1750–1761 e16.
   PubMed Web of Science ®Google Scholar
• Nurse P. A journey in science: cell-cycle control. Mol Med. 2017 Jun;22:112–119.
   PubMedGoogle Scholar
• Hartwell LH. Genetic control of the cell division cycle in yeast. II. Genes controlling DNA replication and its initiation. J Mol Biol. 1971 Jul 14;59(1):183–194.
   PubMed Web of Science ®Google Scholar
• Hartwell LH, Mortimer RK, Culotti J, et al. Genetic control of the cell division cycle in yeast: V. Genetic analysis of cdc mutants. Genetics. 1973 Jun;74(2):267–286.
   PubMed Web of Science ®Google Scholar
• Mitchison JM. The biology of the cell cycle. Cambridge: Cambridge University Press; 1971.
   Google Scholar
• Nurse P. Genetic control of cell size at cell division in yeast. Nature. 1975 Aug 14;256(5518):547–551.
   PubMed Web of Science ®Google Scholar
• Hartwell LH. Saccharomyces cerevisiae cell cycle. Bacteriol Rev. 1974 Jun;38(2):164–198.
   PubMedGoogle Scholar
• Nasmyth KA, Reed SI. Isolation of genes by complementation in yeast: molecular cloning of a cell-cycle gene. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2119–2123.
   PubMed Web of Science ®Google Scholar
• Alfa CE, Booher R, Beach D, et al. Fission yeast cyclin: subcellular localisation and cell cycle regulation. J Cell Sci Suppl. 1989;12:9–19.
   PubMedGoogle Scholar
• Booher RN, Alfa CE, Hyams JS, et al. The fission yeast cdc2/cdc13/suc1 protein kinase: regulation of catalytic activity and nuclear localization. Cell. 1989 Aug 11;58(3):485–497.
   PubMed Web of Science ®Google Scholar
• Hagan I, Hayles J, Nurse P. Cloning and sequencing of the cyclin-related cdc13+ gene and a cytological study of its role in fission yeast mitosis. J Cell Sci. 1988 Dec;91(Pt 4):587–595.
   PubMedGoogle Scholar
• Arnold A, Kim HG, Gaz RD, et al. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest. 1989 Jun;83(6):2034–2040.
   PubMed Web of Science ®Google Scholar
• Meijer L, Arion D, Golsteyn R, et al. Cyclin is a component of the sea urchin egg M-phase specific histone H1 kinase. Embo J. 1989 8;Aug(8):2275–2282.
   Google Scholar
• Xiong Y, Connolly T, Futcher B, et al. Human D-type cyclin. Cell. 1991;65(4):691–699.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Zhang H, Beach D. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell. 1992 Oct 30;71(3):505–514.
   PubMed Web of Science ®Google Scholar
• Matsushime H, Roussel MF, Ashmun RA, et al. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell. 1991;65:701–713.
   PubMed Web of Science ®Google Scholar
• Di Sante G, Di Rocco A, Pupo C, et al. Hormone-induced DNA damage response and repair mediated by cyclin D1 in breast and prostate cancer. Oncotarget. 2017 Oct 10;8(47):81803–81812.
   PubMedGoogle Scholar
• Pestell RG, Albanese C, Reutens AT, et al. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev. 1999;20(4):501–534.
   PubMed Web of Science ®Google Scholar
• Lee YM, Sicinski P. Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human. Cell Cycle. 2006 Sep;5(18):2110–2114.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle kinases in cancer. Curr Opin Genet Dev. 2007 Feb;17(1):60–65.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004 Nov 15;18(22):2699–2711.
   PubMed Web of Science ®Google Scholar
• Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell. 1994;79:573–582.
   PubMed Web of Science ®Google Scholar
• Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323–330.
   PubMed Web of Science ®Google Scholar
• Casimiro MC, Velasco-Velázquez M, Aguirre-Alvarado C, et al. Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present. Expert Opin Investig Drugs. 2014 Mar;23(3):295–304.
   PubMed Web of Science ®Google Scholar
• Fu M, Wang C, Li Z, et al. Minireview: cyclin D1: normal and abnormal functions. Endocrinology. 2004 Dec;145(12):5439–5447.
   PubMed Web of Science ®Google Scholar
• Wang C, Li Z, Lu Y, et al. Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11567–11572.
   PubMed Web of Science ®Google Scholar
• Anders L, Ke N, Hydbring P, et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell. 2011 Nov 15;20(5):620–634.
   PubMed Web of Science ®Google Scholar
• Lee Y, Dominy JE, Choi YJ, et al. Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progression. Nature. 2014 Jun 26;510(7506):547–551.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009 Mar;9(3):153–166.
   PubMed Web of Science ®Google Scholar
• Shupp A, Casimiro MC, Pestell RG. Biological functions of CDK5 and potential CDK5 targeted clinical treatments. Oncotarget. 2017 Mar 7;8(10):17373–17382.
   PubMedGoogle Scholar
• Udvardy A. The role of controlled proteolysis in cell-cycle regulation. Eur J Biochem. 1996 Sep 1;240(2):307–313.
   PubMedGoogle Scholar
• Casimiro MC, Di Sante G, Crosariol M, et al. Kinase-independent role of cyclin D1 in chromosomal instability and mammary tumorigenesis. Oncotarget. 2015 Apr 20;6(11):8525–8538.
   PubMedGoogle Scholar
• Casimiro MC, Arnold A, Pestell RG. Kinase independent oncogenic cyclin D1. Aging (Albany NY). 2015. 7;Jul(7):455–456.
   Google Scholar
• Kato J, Matsushime H, Hiebert SW, et al. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 1993 Mar;7(3):331–342.
   PubMed Web of Science ®Google Scholar
• Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 1998;18(2):753–761.
   PubMed Web of Science ®Google Scholar
• Sherr CJ. Cancer cell cycles. Science. 1996;274:1672–1677.
   PubMed Web of Science ®Google Scholar
• Weinberg RA. E2F and cell proliferation: A world turned upside down. Cell. 1996;85:457–459.
   PubMed Web of Science ®Google Scholar
• Johnson J, Thijssen B, McDermott U, et al. Targeting the RB-E2F pathway in breast cancer. Oncogene. 2016 Sep 15;35(37):4829–4835.
   PubMed Web of Science ®Google Scholar
• Pozo K, Castro-Rivera E, Tan C, et al. The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell. 2013 Oct 14;24(4):499–511.
   PubMed Web of Science ®Google Scholar
• Malumbres M. Cyclin-dependent kinases. Genome Biol. 2014;15(6):122.
   PubMed Web of Science ®Google Scholar
• Bhandari D, Lopez-Sanchez I, To A, et al. Cyclin-dependent kinase 5 activates guanine nucleotide exchange factor GIV/Girdin to orchestrate migration-proliferation dichotomy. Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):E4874–83.
   PubMed Web of Science ®Google Scholar
• Neumeister P, Pixley FJ, Xiong Y, et al. Cyclin D1 governs adhesion and motility of macrophages. Mol Biol Cell. 2003 May;14(5):2005–2015.
   PubMed Web of Science ®Google Scholar
• Fuste NP, Fernandez-Hernandez R, Cemeli T, et al. Cytoplasmic cyclin D1 regulates cell invasion and metastasis through the phosphorylation of paxillin. Nat Commun. 2016 May 16;7:11581.
   PubMed Web of Science ®Google Scholar
• Zhang J, Bu X, Wang H, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018 Jan 4;553(7686):91–95.
   PubMed Web of Science ®Google Scholar
• Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 Aug 24;548(7668):471–475.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57–70.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Xu H, Wu K, Tian Y, et al. CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer. Int J Oncol. 2016 Oct;49(4):1343–1350.
   PubMed Web of Science ®Google Scholar
• Xu HX, Wu KJ, Tian YJ, et al. Expression profile of SIX family members correlates with clinic-pathological features and prognosis of breast cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2016 Jul;95(27):e4085.
   PubMed Web of Science ®Google Scholar
• Knutson TP, Truong TH, Ma S, et al. Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs. J Hematol Oncol. 2017 Apr 17;10(1):89.
   PubMedGoogle Scholar
• Di Lauro L, Pizzuti L, Barba M, et al. Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. J Hematol Oncol. 2015 May;17(8):53.
   Google Scholar
• Albanese C, D’Amico M, Reutens AT, et al. Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. J Biol Chem. 1999 Nov 26;274(48):34186–34195.
   PubMed Web of Science ®Google Scholar
• Motokura T, Bloom T, Kim HG, et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature. 1991 Apr 11;350(6318):512–515.
   PubMed Web of Science ®Google Scholar
• Arnold A, Motokura T, Bloom T, et al. The putative oncogene PRAD1 encodes a novel cyclin. Cold Spring Harb Symp Quant Biol. 1991;56:93–97.
   PubMedGoogle Scholar
• Quelle DE, Ashmun RA, Shurtleff SA, et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 1993 Aug;7(8):1559–1571.
   PubMed Web of Science ®Google Scholar
• Choi YJ, Saez B, Anders L, et al. D-cyclins repress apoptosis in hematopoietic cells by controlling death receptor Fas and its ligand FasL. Dev Cell. 2014 Aug 11;30(3):255–267.
   PubMed Web of Science ®Google Scholar
• Brown NE, Jeselsohn R, Bihani T, et al. Cyclin D1 activity regulates autophagy and senescence in the mammary epithelium. Cancer Res. 2012 Dec 15;72(24):6477–6489.
   PubMed Web of Science ®Google Scholar
• Hanai J, Dhanabal M, Karumanchi SA, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem. 2002 May 10;277(19):16464–16469.
   PubMed Web of Science ®Google Scholar
• Pestell TG, Jiao X, Kumar M, et al. Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. Oncotarget. 2017;8:81754–81775.
   PubMedGoogle Scholar
• Sakamaki T, Casimiro MC, Ju X, et al. Cyclin D1 determines mitochondrial function in vivo. Mol Cell Biol. 2006 Jul;26(14):5449–5469.
   PubMed Web of Science ®Google Scholar
• Bhalla K, Liu WJ, Thompson K, et al. Cyclin D1 represses gluconeogenesis via inhibition of the transcriptional coactivator PGC1alpha. Diabetes. 2014 Oct;63(10):3266–3278.
   PubMed Web of Science ®Google Scholar
• Peiris-Pages M, Martinez-Outschoorn UE, Pestell RG, et al. Cancer stem cell metabolism. Breast Cancer Res. 2016;18(1):55.
   PubMedGoogle Scholar
• Yu Z, Pestell TG, Lisanti MP, et al. Cancer stem cells. Int J Biochem Cell Biol. 2012 Dec;44(12):2144–2151.
   PubMed Web of Science ®Google Scholar
• Luo M, Wicha MS. Targeting cancer stem cell redox metabolism to enhance therapy responses. Semin Radiat Oncol. 2019 Jan;29(1):42–54.
   PubMed Web of Science ®Google Scholar
• Jeselsohn R, Brown NE, Arendt L, et al. Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis. Cancer Cell. 2010 Jan 19;17(1):65–76.
   PubMed Web of Science ®Google Scholar
• Bizen N, Inoue T, Shimizu T, et al. A growth-promoting signaling component cyclin D1 in neural stem cells has antiastrogliogenic function to execute self-renewal. Stem Cells. 2014 Jun;32(6):1602–1615.
   PubMed Web of Science ®Google Scholar
• Ju X, Casimiro MC, Gormley M, et al. Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint. Cancer Res. 2014 Jan 15;74(2):508–519.
   PubMed Web of Science ®Google Scholar
• Matsushime H, Ewen ME, Strom DK, et al. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell. 1992;71:323–334.
   PubMed Web of Science ®Google Scholar
• Meyerson M, Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol. 1994;14(3):2077–2086.
   PubMed Web of Science ®Google Scholar
• Lukas J, Bartkova J, Bartek J. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol. 1996 Dec;16(12):6917–6925.
   PubMed Web of Science ®Google Scholar
• Baldin V, Lukas J, Marcote MJ, et al. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993;7:812–821.
   PubMed Web of Science ®Google Scholar
• Marampon F, Casimiro MC, Fu M, et al. Nerve growth factor regulation of cyclin D1 in PC12 cells through a p21RAS ERK-pathway requires cooperative interactions between Sp1 and NF-kB. Mol Biol Cell. 2008 Jun;19(6):2566–2578.
   PubMed Web of Science ®Google Scholar
• Jiang W, Kahn SM, Zhou P, et al. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene. 1993;8(12):3447–3457.
   PubMed Web of Science ®Google Scholar
• Resnitzky D, Gossen M, Bujard H, et al. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol. 1994;14(3):1669–1679.
   PubMed Web of Science ®Google Scholar
• Wang TC, Cardiff RD, Zukerberg L, et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994 Jun 23;369(6482):669–671.
   PubMed Web of Science ®Google Scholar
• Lee RJ, Albanese C, Fu M, et al. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol. 2000 Jan;20(2):672–683.
   PubMed Web of Science ®Google Scholar
• Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001 Jun 28;411(6841):1017–1021.
   PubMed Web of Science ®Google Scholar
• Robles AI, Rodriguez-Puebla ML, Glick AB, et al. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev. 1998 Aug 15;12(16):2469–2474.
   PubMed Web of Science ®Google Scholar
• Hulit J, Wang C, Li Z, et al. Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol Cell Biol. 2004 Sep;24(17):7598–7611.
   PubMed Web of Science ®Google Scholar
• Wang C, Pattabiraman N, Zhou JN, et al. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol. 2003 Sep;23(17):6159–6173.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ushigome H. Myeloid-derived suppressor cells as a regulator of immunity in organ transplantation. Int J Mol Sci. 2018 Aug 10;19(8):2357.
   Web of Science ®Google Scholar
• Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016 Nov 3;375(18):1767–1778.
   PubMed Web of Science ®Google Scholar
• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016 Mar 2;8(328):328rv4.
   PubMed Web of Science ®Google Scholar
• Dorand RD, Nthale J, Myers JT, et al. Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science. 2016 Jul 22;353(6297):399–403.
   PubMed Web of Science ®Google Scholar
• Yu Z, Wang C, Wang M, et al. A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol. 2008 Aug 11;182(3):509–517.
   PubMed Web of Science ®Google Scholar
• Yu Z, Willmarth NE, Zhou J, et al. microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci U S A. 2010 May 4;107(18):8231–8236.
   PubMed Web of Science ®Google Scholar
• Yu Z, Wang L, Wang C, et al. Cyclin D1 induction of dicer governs microRNA processing and expression in breast cancer. Nat Commun. 2013;4:2812.
   PubMed Web of Science ®Google Scholar
• Hydbring P, Wang Y, Fassl A, et al. Cell-cycle-targeting MicroRNAs as therapeutic tools against refractory cancers. Cancer Cell. 2017 Apr 10;31(4):576–590 e8.
   PubMed Web of Science ®Google Scholar
• Fu M, Wang C, Rao M, et al. Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism. J Biol Chem. 2005 Aug 19;280(33):29728–29742.
   PubMed Web of Science ®Google Scholar
• Neuman E, Ladha MH, Lin N, et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol. 1997 Sep;17(9):5338–5347.
   PubMed Web of Science ®Google Scholar
• Zwijsen RM, Wientjens E, Klompmaker R, et al. CDK-independent activation of estrogen receptor by cyclin D1. Cell. 1997 Feb 7;88(3):405–415.
   PubMed Web of Science ®Google Scholar
• Inoue K, Sherr CJ. Gene expression and cell cycle arrest mediated by transcription factor DMP1 is antagonized by D-type cyclins through a cyclin-dependent-kinase-independent mechanism. Mol Cell Biol. 1998 Mar;18(3):1590–1600.
   PubMed Web of Science ®Google Scholar
• Ganter B, Fu S, Lipsick JS. D-type cyclins repress transcriptional activation by the v-Myb but not the c-Myb DNA-binding domain. Embo J. 1998 Jan 2;17(1):255–268.
   PubMed Web of Science ®Google Scholar
• Pestell RG. New roles of cyclin D1. Am J Pathol. 2013 Jul;183(1):3–9.
   PubMed Web of Science ®Google Scholar
• Knudsen ES, Witkiewicz AK. The strange case of CDK4/6 inhibitors: mechanisms, resistance, and combination strategies. Trends Cancer. 2017 Jan;3(1):39–55.
   PubMed Web of Science ®Google Scholar
• Bienvenu F, Barre B, Giraud S, et al. Transcriptional regulation by a DNA-associated form of cyclin D1. Mol Biol Cell. 2005 Apr;16(4):1850–1858.
   PubMed Web of Science ®Google Scholar
• Fu M, Rao M, Bouras T, et al. Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment. J Biol Chem. 2005 Apr 29;280(17):16934–16941.
   PubMed Web of Science ®Google Scholar
• Bienvenu F, Jirawatnotai S, Elias JE, et al. Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen. Nature. 2010 Jan 21;463(7279):374–378.
   PubMed Web of Science ®Google Scholar
• Albero R, Enjuanes A, Demajo S, et al. Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms. J Clin Invest. 2018 Aug 31;128(9):4132–4147.
   PubMed Web of Science ®Google Scholar
• Pauklin S, Madrigal P, Bertero A, et al. Initiation of stem cell differentiation involves cell cycle-dependent regulation of developmental genes by Cyclin D. Genes Dev. 2016 Feb 15;30(4):421–433.
   PubMed Web of Science ®Google Scholar
• Kollmann K, Heller G, Schneckenleithner C, et al. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell. 2013 Aug 12;24(2):167–181.
   PubMed Web of Science ®Google Scholar
• Otto T, Sicinski P. The kinase-independent, second life of CDK6 in transcription. Cancer Cell. 2013 Aug 12;24(2):141–143.
   PubMed Web of Science ®Google Scholar
• Bellutti F, Tigan AS, Nebenfuehr S, et al. CDK6 antagonizes p53-induced responses during tumorigenesis. Cancer Discov. 2018 Jul;8(7):884–897.
   PubMed Web of Science ®Google Scholar
• Malovannaya A, Lanz RB, Jung SY, et al. Analysis of the human endogenous coregulator complexome. Cell. 2011 May 27;145(5):787–799.
   PubMed Web of Science ®Google Scholar
• Ju BG, Lunyak VV, Perissi V, et al. A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science. 2006 Jun 23;312(5781):1798–1802.
   PubMed Web of Science ®Google Scholar
• Wang C, Fan S, Li Z, et al. Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. Cancer Res. 2005 Aug 1;65(15):6557–6567.
   PubMed Web of Science ®Google Scholar
• Marampon F, Gravina GL, Ju X, et al. Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgenindependent prostate cancer cells to DNA damage. Oncotarget. 2016 Feb 2;7(5):5383–5400.
   Google Scholar
• Casimiro MC, Di Sante G, Ju X, et al. Cyclin D1 promotes androgen-dependent DNA damage repair in prostate cancer cells. Cancer Res. 2016 Jan 15;76(2):329–338.
   PubMed Web of Science ®Google Scholar
• Li Z, Chen K, Jiao X, et al. Cyclin D1 integrates estrogen-mediated DNA damage repair signaling. Cancer Res. 2014 Jul 15;74(14):3959–3970.
   PubMed Web of Science ®Google Scholar
• Li Z, Jiao X, Wang C, et al. Alternative cyclin d1 splice forms differentially regulate the DNA damage response. Cancer Res. 2010 Nov 1;70(21):8802–8811.
   PubMed Web of Science ®Google Scholar
• Jirawatnotai S, Hu Y, Michowski W, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature. 2011 Jun 08;474(7350):230–234.
   PubMed Web of Science ®Google Scholar
• Caldon CE. Estrogen signaling and the DNA damage response in hormone dependent breast cancers. Front Oncol. 2014;4:106.
   PubMedGoogle Scholar
• Levin ER. Minireview: extranuclear steroid receptors: roles in modulation of cell functions. Mol Endocrinol. 2010 Sep 22;25(3):377–384.
   Google Scholar
• Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, et al. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle. 2010 Jun 12;9(12).
   Web of Science ®Google Scholar
• Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004 Nov 18;432(7015):332–337.
   PubMed Web of Science ®Google Scholar
• Mercier I, Casimiro MC, Wang C, et al. Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: implications for the response to hormonal therapy. Cancer Biol Ther. 2008 Aug;7(8):1212–1225.
   PubMed Web of Science ®Google Scholar
• Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999 Apr 1;398(6726):422–426.
   PubMed Web of Science ®Google Scholar
• Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 1999 May 11;96(10):5522–5527.
   PubMed Web of Science ®Google Scholar
• Albanese C, Johnson J, Watanabe G, et al. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem. 1995 Oct 6;270(40):23589–23597.
   PubMed Web of Science ®Google Scholar
• Inoue K, Fry EA. Aberrant expression of cyclin D1 in cancer. Sign Transduct Insights. 2015;4:1–13.
   PubMedGoogle Scholar
• Pontano LL, Diehl JA. DNA damage-dependent cyclin D1 proteolysis: GSK3beta holds the smoking gun. Cell Cycle. 2009 Mar 15;8(6):824–827.
   PubMed Web of Science ®Google Scholar
• Cini G, Carpi A, Mechanick J, et al. Thyroid hormones and the cardiovascular system: pathophysiology and interventions. Biomed Pharmacother. 2009 Dec;63(10):742–753.
   PubMed Web of Science ®Google Scholar
• Gennaro VJ, Stanek TJ, Peck AR, et al. Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells. Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):E9298–E9307.
   PubMed Web of Science ®Google Scholar
• Ganiatsas S, Dow R, Thompson A, et al. A splice variant of Skp2 is retained in the cytoplasm and fails to direct cyclin D1 ubiquitination in the uterine cancer cell line SK-UT. Oncogene. 2001 Jun 21;20(28):3641–3650.
   PubMed Web of Science ®Google Scholar
• Okabe H, Lee SH, Phuchareon J, et al. A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS One. 2006 Dec 27;1:e128.
   PubMed Web of Science ®Google Scholar
• Barbash O, Zamfirova P, Lin DI, et al. Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer. Cancer Cell. 2008 Jul 8;14(1):68–78.
   PubMed Web of Science ®Google Scholar
• Wei S, Yang HC, Chuang HC, et al. A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells. J Biol Chem. 2008 Sep 26;283(39):26759–26770.
   PubMed Web of Science ®Google Scholar
• Agami R, Bernards R. Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell. 2000 Jul 7;102(1):55–66.
   PubMed Web of Science ®Google Scholar
• Russell A, Thompson MA, Hendley J, et al. Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer. Oncogene. 1999 Mar 18;18(11):1983–1991.
   PubMed Web of Science ®Google Scholar
• Diehl JA, Cheng M, Roussel MF, et al. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998 Nov 15;12(22):3499–3511.
   PubMed Web of Science ®Google Scholar
• Casanovas O, Miro F, Estanyol JM, et al. Osmotic stress regulates the stability of cyclin D1 in a p38SAPK2-dependent manner. J Biol Chem. 2000 Nov 10;275(45):35091–35097.
   PubMed Web of Science ®Google Scholar
• Hitomi M, Yang K, Stacey AW, et al. Phosphorylation of cyclin D1 regulated by ATM or ATR controls cell cycle progression. Mol Cell Biol. 2008 Sep;28(17):5478–5493.
   PubMed Web of Science ®Google Scholar
• Vaites LP, Lian Z, Lee EK, et al. ATM deficiency augments constitutively nuclear cyclin D1-driven genomic instability and lymphomagenesis. Oncogene. 2014 Jan 2;33(1):129–133.
   PubMed Web of Science ®Google Scholar
• Aggarwal P, Vaites LP, Kim JK, et al. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell. 2010 Oct 19;18(4):329–340.
   PubMed Web of Science ®Google Scholar
• Li Y, Chitnis N, Nakagawa H, et al. PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers. Cancer Discov. 2015 Mar;5(3):288–303.
   PubMed Web of Science ®Google Scholar
• Hamada T, Keum N, Nishihara R, et al. Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. J Gastroenterol. 2017 Mar;52(3):265–275.
   PubMed Web of Science ®Google Scholar
• Ogino S, Nowak JA, Hamada T, et al. Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology. Annu Rev Pathol. 2019 Jan;24(14):83–103.
   Google Scholar
• Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013 Nov;13(11):800–812.
   PubMed Web of Science ®Google Scholar
• Fernandez MF, Reina-Perez I, Astorga JM, et al. Breast cancer and its relationship with the microbiota. Int J Environ Res Public Health. 2018 Aug 14;15(8):1747–1767.
   Web of Science ®Google Scholar
• Lu J. Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer. J Hematol Oncol. 2015 Aug 13;8:98.
   PubMed Web of Science ®Google Scholar
• Zhang P, Tong Z, Tian F, et al. Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients. J Hematol Oncol. 2016 Aug 11;9(1):68.
   PubMedGoogle Scholar
• Song DG, Ye Q, Poussin M, et al. Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level. J Hematol Oncol. 2016 Jul 20;9(1):56.
   PubMed Web of Science ®Google Scholar
• Yu S, Li A, Liu Q, et al. Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol. 2017 Mar 29;10(1):78.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Pevarello P, Barbacid M, et al. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci. 2008 Jan;29(1):16–21.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 2016 Apr 6;(4):353–367.
   PubMed Web of Science ®Google Scholar
• O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016 Jul;13(7):417–430.
   PubMed Web of Science ®Google Scholar
• Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547–566.
   PubMed Web of Science ®Google Scholar
• Sledge GW Jr., Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017 Sep 1;35(25):2875–2884.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017 Nov 10;35(32):3638–3646.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016 Nov 3;375(18):1738–1748.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016 Apr;17(4):425–439.
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016 Nov 17;375(20):1925–1936.
   PubMed Web of Science ®Google Scholar
• Rader J, Russell MR, Hart LS, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173–6182.
   PubMed Web of Science ®Google Scholar
• Puyol M, Martín A, Dubus P, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell. 2010 Jul 13;18(1):63–73.
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427–1438.
   PubMed Web of Science ®Google Scholar
• Whiteway SL, Harris PS, Venkataraman S, et al. Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells. J Neurooncol. 2013 Jan;111(2):113–121.
   PubMed Web of Science ®Google Scholar
• Rascon K, Flajc G, De Angelis C, et al. Ribociclib in HR+/HER2- advanced or metastatic breast cancer patients. Ann Pharmacother. 2018;7:1060028018817904.
   Google Scholar
• Jansen VM, Bhola NE, Bauer JA, et al. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. Cancer Res. 2017 May 1;77(9):2488–2499.
   PubMed Web of Science ®Google Scholar
• Wu T, Chen Z, To KKW, et al. Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. Biochem Pharmacol. 2017 Jan 15;124:29–42.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012 Jan 15;18(2):568–576.
   PubMed Web of Science ®Google Scholar
• Infante JR, Cassier PA, Gerecitano JF, et al. A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2016 Dec 1;22(23):5696–5705.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Rosen LS, Tolaney SM, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 2016 Jul;6(7):740–753.
   PubMed Web of Science ®Google Scholar
• Lee KWC, Lord S, Finn RS, et al. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. Breast Cancer Res Treat. 2018 Nov 21;174(1):271–278.
   Web of Science ®Google Scholar
• O’Leary B, Hrebien S, Morden JP, et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat Commun. 2018 Mar 1;9(1):896.
   PubMedGoogle Scholar
• Cristofanilli M. Inflammatory breast cancer: a new approach. Lancet Oncol. 2016 May;17(5):544–546.
   PubMed Web of Science ®Google Scholar
• O’Leary B, Cutts RJ, Liu Y, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018 Nov;8(11):1390–1403.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018 Jul 1;29(7):1541–1547.
   PubMed Web of Science ®Google Scholar
• Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015 Jul 16;373(3):209–219.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018 Aug 20;36(24):2465–2472.
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25–35.
   PubMed Web of Science ®Google Scholar
• Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018 Nov 15;379(20):1926–1936.
   PubMed Web of Science ®Google Scholar
• Lew J, Huang QQ, Qi Z, et al. A brain-specific activator of cyclin-dependent kinase 5. Nature. 1994 Sep 29;371(6496):423–426.
   PubMed Web of Science ®Google Scholar
• Tsai LH, Delalle I, Caviness VS Jr., et al. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature. 1994 Sep 29;371(6496):419–423.
   PubMed Web of Science ®Google Scholar
• Sharpless NE, Sherr CJ. Forging a signature of in vivo senescence. Nat Rev Cancer. 2015 Jul;15(7):397–408.
   PubMed Web of Science ®Google Scholar
• Dean JL, Thangavel C, McClendon AK, et al. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 2010 Jul 15;29(28):4018–4032.
   PubMed Web of Science ®Google Scholar
• Ismail A, Bandla S, Reveiller M, et al. Early G(1) cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma. Clin Cancer Res. 2011 Jul 1;17(13):4513–4522.
   PubMed Web of Science ®Google Scholar
• Dean JL, McClendon AK, Hickey TE, et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle. 2012 Jul 15;11(14):2756–2761.
   PubMed Web of Science ®Google Scholar
• Franco J, Witkiewicz AK, Knudsen ES. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget. 2014 Aug 15;5(15):6512–6525.
   PubMed Web of Science ®Google Scholar
• Heilmann AM, Perera RM, Ecker V, et al. CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers. Cancer Res. 2014 Jul 15;74(14):3947–3958.
   PubMed Web of Science ®Google Scholar
• Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol. 2005 Jun 20;23(18):4215–4224.
   PubMed Web of Science ®Google Scholar
• D’Amico M, Wu K, Di Vizio D, et al. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis. Cancer Res. 2003 Jun 15;63(12):3395–3402.
   PubMed Web of Science ®Google Scholar
• Shin E, Jung WH, Koo JS. Expression of p16 and pRB in invasive breast cancer. Int J Clin Exp Pathol. 2015;8(7):8209–8217.
   PubMed Web of Science ®Google Scholar
• Dublin EA, Patel NK, Gillett CE, et al. Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int J Cancer. 1998 Feb 20;79(1):71–75.
   PubMed Web of Science ®Google Scholar
• Hui R, Macmillan RD, Kenny FS, et al. INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res. 2000 Jul;6(7):2777–2787.
   PubMed Web of Science ®Google Scholar
• Anderson JJ, Tiniakos DG, McIntosh GG, et al. Retinoblastoma protein in human breast carcinoma: immunohistochemical study using a new monoclonal antibody effective on routinely processed tissues. J Pathol. 1996 Sep;180(1):65–70.
   PubMed Web of Science ®Google Scholar
• Herrera-Abreu MT, Palafox M, Asghar U, et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 2016 Apr 15;76(8):2301–2313.
   PubMed Web of Science ®Google Scholar
• Kovatcheva M, Liu DD, Dickson MA, et al. MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget. 2015 Apr 10;6(10):8226–8243.
   PubMedGoogle Scholar
• Gul A, Leyland-Jones B, Dey N, et al. A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach. Am J Cancer Res. 2018;8(12):2359–2376.
   PubMed Web of Science ®Google Scholar
• Yang C, Li Z, Bhatt T, et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene. 2017 Apr 20;36(16):2255–2264.
   PubMed Web of Science ®Google Scholar
• Raspe E, Coulonval K, Pita JM, et al. CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib. EMBO Mol Med. 2017 Aug;9(8):1052–1066.
   PubMed Web of Science ®Google Scholar
• Ji W, Shi Y, Wang X, et al. Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib. Int J Biol Sci. 2019;15(3):522–532.
   PubMed Web of Science ®Google Scholar
• Vora SR, Juric D, Kim N, et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell. 2014 Jul 14;26(1):136–149.
   PubMed Web of Science ®Google Scholar
• Li Z, Jiao X, Di Sante G, et al. Cyclin D1 integrates G9a-mediated histone methylation. Oncogene. 2019 Feb 4:18. DOI:10.1038/s41388-019-0723-8.
   Google Scholar
• Bisi JE, Sorrentino JA, Jordan JL, et al. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors. Oncotarget. 2017 Jun 27;8(26):42343–42358.
   PubMedGoogle Scholar
• Casimiro MC, Pestell RG. Cyclin d1 induces chromosomal instability. Oncotarget. 2012 Mar;3(3):224–225.
   PubMedGoogle Scholar